Join editorial board member Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA) as he explores the potential of navtemadlin, an oral MDM2 inhibitor, as a treatment option for myelofibrosis. He discusses thehey take-aways from the BOREAS study, including its disease-modifying impact in patients relapsed or refractory to JAK inhibitors, […]

Prof Rachel Rau (University of Washington, Seattle Children’s Hospital, Seattle, WA, USA) joins touchHAEMATOLOGY to discuss the findings from the phase 3 AALL1731 study, a plenary session presented at the 66th ASH Annual Meeting & Exposition.  This pivotal trial evaluated blinatumomab, an innovative immunotherapy, in children with NCI standard risk B-cell acute lymphoblastic leukemia (B-ALL). […]